PharmaShots | Incisive News in 3 Shots

Subscribe Now

Jazz

Jazz’ Enrylaze Receives EC’s Approval for the Treatment of Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma

Jazz’ Enrylaze Receives EC’s Approval for the Treatment of Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma

September 22, 2023

Jazz and Zymeworks Present P-IIb Trial (HERIZON-BTC-01) Results of Zanidatamab for HER2-Amplified Biliary Tract Cancers at ASCO 2023

Jazz and Zymeworks Present P-IIb Trial (HERIZON-BTC-01) Results of Zanidatamab for HER2-Amplified Biliary Tract Cancers at ASCO 20...

June 5, 2023

Jazz Entered into an Exclusive License Agreement with Zymeworks to Develop and Commercialize Zanidatamab for Cancers

Jazz Entered into an Exclusive License Agreement with Zymeworks to Develop and Commercialize Zanidatamab for Cancers

October 19, 2022

Jazz Reports the Initiation of Epidiolex/Epidyolex (cannabidiol) in P-III (GWEP20238) Trial for Epilepsy Associated with Myoclonic-Atonic Seizures

Jazz Reports the Initiation of Epidiolex/Epidyolex (cannabidiol) in P-III (GWEP20238) Trial for Epilepsy Associated with Myoclonic...

August 19, 2022

Jazz Reports Results of Nabiximols Oromucosal Spray in P-III (RELEASE MSS1) Trial for the Treatment of Multiple Sclerosis Spasticity

Jazz Reports Results of Nabiximols Oromucosal Spray in P-III (RELEASE MSS1) Trial for the Treatment of Multiple Sclerosis Spastici...

June 29, 2022

Jazz Entered into an Exclusive License Agreement with Sumitomo Pharma to Develop and Commercialize DSP-0187 for the Treatment of Sleep Disorders

Jazz Entered into an Exclusive License Agreement with Sumitomo Pharma to Develop and Commercialize DSP-0187 for the Treatment of S...

May 5, 2022

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us